Literature DB >> 14718596

Suppression of 15-hydroxyprostaglandin dehydrogenase messenger RNA concentration, protein expression, and enzymatic activity during human ureteral obstruction.

Travis J Jerde1, William S Mellon, Susan M Fischer, Monica Liebert, Dale E Bjorling, Stephen Y Nakada.   

Abstract

Prostanoids produce significant effects in the ureter, particularly in response to obstruction. Ureteral obstruction is associated with increased prostanoid synthesis via cyclooxygenase induction; however, prostaglandin degradation mediated by 15-hydroxyprostaglandin dehydrogenase (PGDH) has not been evaluated in the ureter. The purpose of this study was to determine whether PGDH steady-state mRNA, protein, and enzyme activity are altered in the human ureter during obstruction. Human ureteral segments from patients undergoing donor nephrectomy (normal segments) or ureteral stricture repair (obstructed segments) were obtained with proper informed consent. We evaluated PGDH steady-state mRNA relative to ribosomal protein S26 reference gene by reverse transcription-polymerase chain reaction and Vistra Green fluoroimaging. We determined PGDH protein content relative to glyceraldehyde-3-phosphate dehydrogenase by immunoblotting and PGDH localization by immunohistochemistry. PGDH enzymatic activity was determined by measurement of conversion of 15-hydroxy- to 15-keto-prostaglandin using thin layer chromatography separation. We found that PGDH mRNA and protein were decreased 4- to 6-fold, and enzyme activity was decreased >3-fold in obstructed human ureter relative to normal controls. PGDH was localized to the urothelial cells, with little or no expression in smooth muscle. Our results indicate that PGDH mRNA, protein, and enzyme activity are suppressed in the human ureter during obstruction. Increased concentrations of prostanoids subsequent to ureteral obstruction seem to be due to decreased degradation as well as increased synthesis. Modulation of prostanoid degradation may have therapeutic relevance in obstructive disorders of the ureter.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718596     DOI: 10.1124/jpet.103.056929

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Loss of 15-hydroxyprostaglandin dehydrogenase expression disrupts urothelial differentiation.

Authors:  Stephanie Tseng-Rogenski; I-Ling Lee; Daniel Gebhardt; Susan M Fischer; Christopher Wood; John M Park; Monica Liebert
Journal:  Urology       Date:  2008-02       Impact factor: 2.649

Review 2.  Medical expulsive therapy for distal ureteral stones.

Authors:  Vassilios Tzortzis; Charalampos Mamoulakis; Jorge Rioja; Stavros Gravas; Martin C Michel; Jean J M C H de la Rosette
Journal:  Drugs       Date:  2009       Impact factor: 9.546

3.  The common parasite Toxoplasma gondii induces prostatic inflammation and microglandular hyperplasia in a mouse model.

Authors:  Darrelle L Colinot; Tamila Garbuz; Maarten C Bosland; Liang Wang; Susan E Rice; William J Sullivan; Gustavo Arrizabalaga; Travis J Jerde
Journal:  Prostate       Date:  2017-05-12       Impact factor: 4.104

4.  Effects of 4-hydroxy-nonenal and Amyloid-beta on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells.

Authors:  Rui Wang; Suqing Wang; James S Malter; Deng-Shun Wang
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

5.  Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders.

Authors:  Prerna Rastogi; Alice Rickard; Nikolay Dorokhov; David J Klumpp; Jane McHowat
Journal:  Am J Physiol Renal Physiol       Date:  2008-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.